Budipine

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.^[2][3][4]

Budipine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N04BX03 (WHO)
Identifiers
IUPAC name 1-tert-butyl-4,4-diphenylpiperidine[1]
CAS Number	57982-78-2 Y
PubChem CID	68778
ChemSpider	62021 Y
UNII	L9026OPI2Z
KEGG	D07306 Y
ChEMBL	ChEMBL334491 Y
CompTox Dashboard (EPA)	DTXSID20206709
ECHA InfoCard	100.055.494
Chemical and physical data
Formula	C21H27N
Molar mass	293.454 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3
InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 Y Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N Y
(verify)

While its exact mechanism of action is not well characterized,^[2] it is believed to be an NMDA receptor antagonist,^[5][6] but also promoting the synthesis of dopamine.^[7]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.^[7][8]

It is an hERG blocker and can produce long QT syndrome as a side effect.^[9]

Analogues include prodipine and medipine.^[10][11]

Synthesis

Budipine can be prepared from the 1-tert-butyl-4-piperidone [1465-76-5] directly by treatment with benzene in the presence triflic acid.^[12] This method of synthesis enables a 99% yield of product.

Thieme Synthesis:^[13]

4-Phenyl-1-t-butyl-4-piperidinol,^[14] (1)

1-t-butyl-3-benzoyl-4-phenyl-4-piperidinol [81831-81-4] (3)

See also

• AD-1211
• Delucemine
• Diphenidine
• Ephenidine
• Fluorolintane
• Lanicemine
• Methoxphenidine (MXP)
• MT-45
• Remacemide